The University of Southampton
University of Southampton Institutional Repository

Differential efficacy from the addition of bortezomib to R-CHOP in diffuse large B-cell lymphoma according to the molecular subgroup in the REMoDL-B study with a 5-year follow-up

Differential efficacy from the addition of bortezomib to R-CHOP in diffuse large B-cell lymphoma according to the molecular subgroup in the REMoDL-B study with a 5-year follow-up
Differential efficacy from the addition of bortezomib to R-CHOP in diffuse large B-cell lymphoma according to the molecular subgroup in the REMoDL-B study with a 5-year follow-up

Clinical trials frequently include multiple end points that mature at different times. The initial report, typically based on the primary end point, may be published when key planned co-primary or secondary analyses are not yet available. Clinical Trial Updates provide an opportunity to disseminate additional results from studies, published in JCO or elsewhere, for which the primary end point has already been reported.The REMoDL-B phase III adaptive trial compared rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone (R-CHOP) versus R-CHOP + bortezomib (RB-CHOP) in patients with diffuse large B-cell lymphoma (DLBCL), stratified by molecular subtype. Primary analysis at a median follow-up of 30 months found no effect of bortezomib on progression-free survival (PFS) or overall survival (OS). Retrospective analysis using a gene expression-based classifier identified a molecular high-grade (MHG) group with worse outcomes. We present an updated analysis for patients successfully classified by the gene expression profile (GEP). Eligible patients were age older than 18 years with untreated DLBCL, fit enough for full-dose chemotherapy, and with adequate biopsies for GEP. Of 1,077 patients registered, 801 were identified with Activated B-Cell (ABC), Germinal Center B-cell, or MHG lymphoma. At a median follow-up of 64 months, there was no overall benefit of bortezomib on PFS or OS (5-year PFS hazard ratio [HR], 0.81; P = .085; OS HR, 0.86; P = .32). However, improved PFS and OS were seen in ABC lymphomas after RB-CHOP: 5-year OS 67% with R-CHOP versus 80% with RB-CHOP (HR, 0.58; 95% CI, 0.35 to 0.95; P = .032). Five-year PFS was higher in MHG lymphomas: 29% versus 55% (HR, 0.46; 95% CI, 0.26 to 0.84). Patients with ABC and MHG DLBCL may benefit from the addition of bortezomib to R-CHOP in initial therapy.

1527-7755
2718-2723
Davies, Andrew J.
6289b5e8-da1b-4189-b7ff-ac6ecf147afb
Barrans, Sharon
0d135b1f-3a6b-4aed-9d43-7cf343f11fa9
Stanton, Louise
99620a6d-61b5-404a-8ddc-6c74b1e751b6
Caddy, Josh
c9f48059-2d70-45e4-a80a-978bf74fac34
Wilding, Sam
a026cae1-cc72-49b5-a52b-ec1d931d72e1
Saunders, Geoff
077e86b5-fd57-4ee5-bac1-2d94be637975
Mamot, Christoph
40d9310f-6633-4051-b0e8-50cd681cee29
Novak, Urban
17fe7a01-bfad-4cb7-b5cf-149c70f234e5
McMillan, Andrew
874e0f5d-764b-45bb-9baa-d2e4ce06837d
Fields, Paul
6344a2dc-2b25-4669-bec5-c3097cbb70c6
Collins, Graham P.
450338cb-2bb0-4cef-90a7-7bcd47a12e2f
Stephens, Richard
fd5906e4-8b8e-465c-b5c2-55e1f884492f
Cucco, Francesco
4592e677-378e-40cf-81bb-1c9a3dfc16df
Sha, Chulin
26db1360-a628-47b4-8b53-e4d5b07eaf31
van Hoppe, Moniek
c5ad6d6e-5442-429d-8be5-5348d4703dae
Tooze, Reuben
e82e0595-1ca2-4886-8f86-af9af62c4ed0
Davies, John R.
a2048855-13fe-481e-9e4c-4b16439d81c1
Griffiths, Gareth
62854d61-4904-4fac-9f4f-cdbd44a4679a
Schuh, Anna
aed67f76-030c-43b5-9907-601d6ab4a379
Burton, Catherine
c495cd04-33e5-475b-887d-56689a582e6c
Westhead, David R.
08938232-27c4-444e-8e6e-0659a7dea913
Du, Ming-Qing
e5958a4b-4cae-4ed3-acab-f79da2ed4071
Johnson, Peter W.M.
1afe5cab-d45a-4cfe-91d9-d212e03cf1f2
Davies, Andrew J.
6289b5e8-da1b-4189-b7ff-ac6ecf147afb
Barrans, Sharon
0d135b1f-3a6b-4aed-9d43-7cf343f11fa9
Stanton, Louise
99620a6d-61b5-404a-8ddc-6c74b1e751b6
Caddy, Josh
c9f48059-2d70-45e4-a80a-978bf74fac34
Wilding, Sam
a026cae1-cc72-49b5-a52b-ec1d931d72e1
Saunders, Geoff
077e86b5-fd57-4ee5-bac1-2d94be637975
Mamot, Christoph
40d9310f-6633-4051-b0e8-50cd681cee29
Novak, Urban
17fe7a01-bfad-4cb7-b5cf-149c70f234e5
McMillan, Andrew
874e0f5d-764b-45bb-9baa-d2e4ce06837d
Fields, Paul
6344a2dc-2b25-4669-bec5-c3097cbb70c6
Collins, Graham P.
450338cb-2bb0-4cef-90a7-7bcd47a12e2f
Stephens, Richard
fd5906e4-8b8e-465c-b5c2-55e1f884492f
Cucco, Francesco
4592e677-378e-40cf-81bb-1c9a3dfc16df
Sha, Chulin
26db1360-a628-47b4-8b53-e4d5b07eaf31
van Hoppe, Moniek
c5ad6d6e-5442-429d-8be5-5348d4703dae
Tooze, Reuben
e82e0595-1ca2-4886-8f86-af9af62c4ed0
Davies, John R.
a2048855-13fe-481e-9e4c-4b16439d81c1
Griffiths, Gareth
62854d61-4904-4fac-9f4f-cdbd44a4679a
Schuh, Anna
aed67f76-030c-43b5-9907-601d6ab4a379
Burton, Catherine
c495cd04-33e5-475b-887d-56689a582e6c
Westhead, David R.
08938232-27c4-444e-8e6e-0659a7dea913
Du, Ming-Qing
e5958a4b-4cae-4ed3-acab-f79da2ed4071
Johnson, Peter W.M.
1afe5cab-d45a-4cfe-91d9-d212e03cf1f2

Davies, Andrew J., Barrans, Sharon, Stanton, Louise, Caddy, Josh, Wilding, Sam, Saunders, Geoff, Mamot, Christoph, Novak, Urban, McMillan, Andrew, Fields, Paul, Collins, Graham P., Stephens, Richard, Cucco, Francesco, Sha, Chulin, van Hoppe, Moniek, Tooze, Reuben, Davies, John R., Griffiths, Gareth, Schuh, Anna, Burton, Catherine, Westhead, David R., Du, Ming-Qing and Johnson, Peter W.M. (2023) Differential efficacy from the addition of bortezomib to R-CHOP in diffuse large B-cell lymphoma according to the molecular subgroup in the REMoDL-B study with a 5-year follow-up. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 41 (15), 2718-2723. (doi:10.1200/JCO.23.00033).

Record type: Article

Abstract

Clinical trials frequently include multiple end points that mature at different times. The initial report, typically based on the primary end point, may be published when key planned co-primary or secondary analyses are not yet available. Clinical Trial Updates provide an opportunity to disseminate additional results from studies, published in JCO or elsewhere, for which the primary end point has already been reported.The REMoDL-B phase III adaptive trial compared rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone (R-CHOP) versus R-CHOP + bortezomib (RB-CHOP) in patients with diffuse large B-cell lymphoma (DLBCL), stratified by molecular subtype. Primary analysis at a median follow-up of 30 months found no effect of bortezomib on progression-free survival (PFS) or overall survival (OS). Retrospective analysis using a gene expression-based classifier identified a molecular high-grade (MHG) group with worse outcomes. We present an updated analysis for patients successfully classified by the gene expression profile (GEP). Eligible patients were age older than 18 years with untreated DLBCL, fit enough for full-dose chemotherapy, and with adequate biopsies for GEP. Of 1,077 patients registered, 801 were identified with Activated B-Cell (ABC), Germinal Center B-cell, or MHG lymphoma. At a median follow-up of 64 months, there was no overall benefit of bortezomib on PFS or OS (5-year PFS hazard ratio [HR], 0.81; P = .085; OS HR, 0.86; P = .32). However, improved PFS and OS were seen in ABC lymphomas after RB-CHOP: 5-year OS 67% with R-CHOP versus 80% with RB-CHOP (HR, 0.58; 95% CI, 0.35 to 0.95; P = .032). Five-year PFS was higher in MHG lymphomas: 29% versus 55% (HR, 0.46; 95% CI, 0.26 to 0.84). Patients with ABC and MHG DLBCL may benefit from the addition of bortezomib to R-CHOP in initial therapy.

Text
jco.23.00033 - Version of Record
Download (315kB)

More information

Accepted/In Press date: 10 February 2023
e-pub ahead of print date: 27 March 2023
Published date: 27 March 2023
Additional Information: Funding Information: Supported by a grant from Janssen-Cilag and endorsed by Cancer Research UK (C328/A12128). Translational work was supported by a Blood Cancer UK specialist program grant to the Precision Medicine for Aggressive Lymphoma consortium (15002).The Southampton Clinical Trials Unit receives core funding from Cancer Research UK. The study was supported by the National Institute for Healthcare Research and Cancer Research UK Experimental Cancer Medicine Centres at Southampton, Oxford, and Cambridge, UK. Publisher Copyright: © American Society of Clinical Oncology.

Identifiers

Local EPrints ID: 477483
URI: http://eprints.soton.ac.uk/id/eprint/477483
ISSN: 1527-7755
PURE UUID: fb863412-5a03-4024-a56e-50ac5b110c36
ORCID for Sam Wilding: ORCID iD orcid.org/0000-0003-4184-2821
ORCID for Paul Fields: ORCID iD orcid.org/0000-0002-3189-6298

Catalogue record

Date deposited: 07 Jun 2023 16:43
Last modified: 27 Mar 2024 02:58

Export record

Altmetrics

Contributors

Author: Andrew J. Davies
Author: Sharon Barrans
Author: Louise Stanton
Author: Josh Caddy
Author: Sam Wilding ORCID iD
Author: Geoff Saunders
Author: Christoph Mamot
Author: Urban Novak
Author: Andrew McMillan
Author: Paul Fields ORCID iD
Author: Graham P. Collins
Author: Richard Stephens
Author: Francesco Cucco
Author: Chulin Sha
Author: Moniek van Hoppe
Author: Reuben Tooze
Author: John R. Davies
Author: Gareth Griffiths
Author: Anna Schuh
Author: Catherine Burton
Author: David R. Westhead
Author: Ming-Qing Du
Author: Peter W.M. Johnson

Download statistics

Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.

View more statistics

Atom RSS 1.0 RSS 2.0

Contact ePrints Soton: eprints@soton.ac.uk

ePrints Soton supports OAI 2.0 with a base URL of http://eprints.soton.ac.uk/cgi/oai2

This repository has been built using EPrints software, developed at the University of Southampton, but available to everyone to use.

We use cookies to ensure that we give you the best experience on our website. If you continue without changing your settings, we will assume that you are happy to receive cookies on the University of Southampton website.

×